| Source: |
| Type: |
| Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms: 1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion. 2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue. 3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment. 4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream. 5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body. 6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection. 7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs. 8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis. |
| 5260- | 3BP, | Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer |
| - | in-vivo, | PC, | NA |
| 1333- | AG, | Astragalus polysaccharide inhibits breast cancer cell migration and invasion by regulating epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway |
| - | in-vitro, | BC, | NA |
| 1338- | AG, | The Modulatory Properties of Astragalus membranaceus Treatment on Triple-Negative Breast Cancer: An Integrated Pharmacological Method |
| - | in-vitro, | BC, | NA |
| 5431- | AG, | Advances in research on the anti-tumor mechanism of Astragalus polysaccharides |
| - | Review, | Var, | NA |
| 5433- | AG, | Mechanisms of astragalus polysaccharide enhancing STM2457 therapeutic efficacy in m6A-mediated OSCC treatment |
| - | vitro+vivo, | OS, | NA |
| 5438- | AG, | Mechanisms of astragalus polysaccharide enhancing STM2457 therapeutic efficacy in mA-mediated OSCC treatment |
| - | vitro+vivo, | NA, | NA |
| 4426- | AgNPs, | Antiangiogenic properties of silver nanoparticles |
| - | Study, | NA, | NA |
| 5147- | AgNPs, | Size dependent anti-invasiveness of silver nanoparticles in lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 359- | AgNPs, | Anti-cancer & anti-metastasis properties of bioorganic-capped silver nanoparticles fabricated from Juniperus chinensis extract against lung cancer cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HEK293 |
| 5343- | Ajoene, | The garlic compound ajoene covalently binds vimentin, disrupts the vimentin network and exerts anti-metastatic activity in cancer cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | BC, | MDA-MB-231 |
| 3442- | ALA, | α‑lipoic acid modulates prostate cancer cell growth and bone cell differentiation |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | C4-2B | - | in-vitro, | Nor, | 3T3 |
| 297- | ALA, | Insights on the Use of α-Lipoic Acid for Therapeutic Purposes |
| - | Review, | BC, | SkBr3 | - | Review, | neuroblastoma, | SK-N-SH | - | Review, | AD, | NA |
| 1124- | ALA, | Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells |
| - | in-vitro, | Thyroid, | BCPAP | - | in-vitro, | Thyroid, | HTH-83 | - | in-vitro, | Thyroid, | CAL-62 | - | in-vitro, | Thyroid, | FTC-133 | - | in-vivo, | NA, | NA |
| 1252- | aLinA, | α-Linolenic acid induces apoptosis, inhibits the invasion and metastasis, and arrests cell cycle in human breast cancer cells by inhibiting fatty acid synthase |
| - | in-vitro, | BC, | NA |
| 1157- | And, | Andrographolide suppresses the migratory ability of human glioblastoma multiforme cells by targeting ERK1/2-mediated matrix metalloproteinase-2 expression |
| - | in-vitro, | GBM, | GBM8401 | - | in-vitro, | GBM, | U251 |
| 1548- | Api, | A comprehensive view on the apigenin impact on colorectal cancer: Focusing on cellular and molecular mechanisms |
| - | Review, | Colon, | NA |
| 1565- | Api, | Apigenin-7-glucoside induces apoptosis and ROS accumulation in lung cancer cells, and inhibits PI3K/Akt/mTOR pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | BEAS-2B | - | in-vitro, | Lung, | H1975 |
| 1545- | Api, | The Potential Role of Apigenin in Cancer Prevention and Treatment |
| - | Review, | NA, | NA |
| 2632- | Api, | Apigenin inhibits migration and induces apoptosis of human endometrial carcinoma Ishikawa cells via PI3K-AKT-GSK-3β pathway and endoplasmic reticulum stress |
| - | in-vitro, | EC, | NA |
| 2640- | Api, | Apigenin: A Promising Molecule for Cancer Prevention |
| - | Review, | Var, | NA |
| 2641- | Api, | Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 2593- | Api, | Apigenin promotes apoptosis of 4T1 cells through PI3K/AKT/Nrf2 pathway and improves tumor immune microenvironment in vivo |
| - | in-vivo, | BC, | 4T1 |
| 175- | Api, | Apigenin up-regulates transgelin and inhibits invasion and migration of colorectal cancer through decreased phosphorylation of AKT |
| - | vitro+vivo, | CRC, | SW480 | - | vitro+vivo, | CRC, | DLD1 | - | vitro+vivo, | CRC, | LS174T |
| 172- | Api, | Apigenin suppresses colorectal cancer cell proliferation, migration and invasion via inhibition of the Wnt/β-catenin signaling pathway |
| - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | HTC15 |
| 174- | Api, | Downregulation of NEDD9 by apigenin suppresses migration, invasion, and metastasis of colorectal cancer cells |
| - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | DLD1 |
| 3396- | ART/DHA, | Progress on the study of the anticancer effects of artesunate |
| - | Review, | Var, | NA |
| 574- | ART/DHA, | Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway |
| 570- | ART/DHA, | Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling |
| - | vitro+vivo, | NSCLC, | A549 | - | vitro+vivo, | NSCLC, | H1299 |
| 1099- | ART/DHA, | Dihydroartemisinin inhibits IL-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway |
| - | in-vitro, | NA, | NA |
| 5415- | ASA, | The Anti-Metastatic Role of Aspirin in Cancer: A Systematic Review |
| - | Review, | Var, | NA |
| 5398- | Ash, | Withaferin-A inhibits colorectal cancer growth and metastasis by targeting the HSP90/HIF-1α/EMT axis |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
| 3174- | Ash, | Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | Hep3B | - | in-vitro, | HCC, | HUH7 |
| 3172- | Ash, | Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | Nor, | HL7702 |
| 1358- | Ash, | Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms |
| - | Review, | Var, | NA |
| 1181- | Ash, | Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| 1173- | Ash, | Withaferin A inhibits proliferation of human endometrial cancer cells via transforming growth factor-β (TGF-β) signalling |
| - | in-vitro, | EC, | K1 | - | in-vitro, | Nor, | THESCs |
| 5172- | Ash, | Withaferin-A suppress AKT induced tumor growth in colorectal cancer cells |
| 5384- | AsP, | MEL, | Synergistic Anticancer Effect of Melatonin and Ascorbyl Palmitate Nanoformulation: A Promising Combination for Cancer Therapy |
| - | in-vivo, | Var, | NA |
| 4820- | ASTX, | Astaxanthin suppresses the malignant behaviors of nasopharyngeal carcinoma cells by blocking PI3K/AKT and NF-κB pathways via miR-29a-3p |
| - | in-vitro, | NPC, | NA |
| 4808- | ASTX, | Anti-Tumor Effects of Astaxanthin by Inhibition of the Expression of STAT3 in Prostate Cancer |
| - | in-vitro, | Pca, | DU145 | - | in-vivo, | NA, | NA |
| 5362- | AV, | Anti-cancer effects of aloe-emodin: a systematic review |
| - | Review, | Var, | NA |
| 5250- | Ba, | Exploring baicalein: A natural flavonoid for enhancing cancer prevention and treatment |
| - | Review, | Var, | NA |
| 5251- | Ba, | The Fascinating Effects of Baicalein on Cancer: A Review |
| - | Review, | Var, | NA |
| 2606- | Ba, | Baicalein: A review of its anti-cancer effects and mechanisms in Hepatocellular Carcinoma |
| - | Review, | HCC, | NA |
| 2296- | Ba, | The most recent progress of baicalein in its anti-neoplastic effects and mechanisms |
| - | Review, | Var, | NA |
| 5536- | BBM, | Regulation of Cell-Signaling Pathways by Berbamine in Different Cancers |
| - | Review, | Var, | NA |
| 5540- | BBM, | Berbamine Inhibits Cell Proliferation and Migration and Induces Cell Death of Lung Cancer Cells via Regulating c-Maf, PI3K/Akt, and MDM2-P53 Pathways |
| - | vitro+vivo, | NSCLC, | NA |
| 5555- | BBM, | Berbamine inhibits cell proliferation and invasion by increasing FTO expression in renal cell carcinoma cells |
| - | vitro+vivo, | RCC, | NA |
| 2700- | BBR, | Cell-specific pattern of berberine pleiotropic effects on different human cell lines |
| - | in-vitro, | GBM, | U343 | - | in-vitro, | GBM, | MIA PaCa-2 | - | in-vitro, | Nor, | HDFa |
| 2694- | BBR, | Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells |
| - | in-vitro, | BC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:324 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid